CR20230542A - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
CR20230542A
CR20230542A CR20230542A CR20230542A CR20230542A CR 20230542 A CR20230542 A CR 20230542A CR 20230542 A CR20230542 A CR 20230542A CR 20230542 A CR20230542 A CR 20230542A CR 20230542 A CR20230542 A CR 20230542A
Authority
CR
Costa Rica
Prior art keywords
trex1
modulators
compositions
treating
compounds
Prior art date
Application number
CR20230542A
Other languages
English (en)
Inventor
Jonathan E Wilson
Avinash Khanna
Jennifer L Rocnik
Aaron Coffin
Julian R Levell
William T Mcelroy
Mary-Margaret Zablocki
David J Guerin
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CR20230542A publication Critical patent/CR20230542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de Fórmula (I): (I); y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para el tratamiento de una variedad de condiciones asociadas con la TREX1.<br />
CR20230542A 2021-04-26 2022-04-25 Moduladores de trex1 CR20230542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179723P 2021-04-26 2021-04-26
PCT/US2022/026103 WO2022232004A1 (en) 2021-04-26 2022-04-25 Modulators of trex1

Publications (1)

Publication Number Publication Date
CR20230542A true CR20230542A (es) 2024-03-19

Family

ID=81598085

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230542A CR20230542A (es) 2021-04-26 2022-04-25 Moduladores de trex1

Country Status (20)

Country Link
US (1) US20240246946A1 (es)
EP (1) EP4330254A1 (es)
JP (1) JP2024517715A (es)
KR (1) KR20240028979A (es)
CN (1) CN117545754A (es)
AR (1) AR125448A1 (es)
AU (1) AU2022264711A1 (es)
BR (1) BR112023022298A2 (es)
CA (1) CA3216752A1 (es)
CL (1) CL2023003168A1 (es)
CO (1) CO2023015732A2 (es)
CR (1) CR20230542A (es)
DO (1) DOP2023000236A (es)
EC (1) ECSP23088732A (es)
IL (1) IL308016A (es)
JO (1) JOP20230271A1 (es)
MX (1) MX2023012678A (es)
PE (1) PE20242223A1 (es)
TW (1) TW202309019A (es)
WO (1) WO2022232004A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151567A1 (en) * 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
PT3891145T (pt) * 2018-12-06 2023-07-18 Constellation Pharmaceuticals Inc Moduladores de trex1
EP4003985A1 (en) * 2019-07-23 2022-06-01 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
WO2022232004A1 (en) 2022-11-03
IL308016A (en) 2023-12-01
JP2024517715A (ja) 2024-04-23
CO2023015732A2 (es) 2024-02-05
MX2023012678A (es) 2024-02-08
ECSP23088732A (es) 2024-02-29
EP4330254A1 (en) 2024-03-06
AR125448A1 (es) 2023-07-19
CN117545754A (zh) 2024-02-09
KR20240028979A (ko) 2024-03-05
AU2022264711A1 (en) 2023-11-09
CA3216752A1 (en) 2022-11-03
JOP20230271A1 (ar) 2023-10-26
TW202309019A (zh) 2023-03-01
PE20242223A1 (es) 2024-11-19
DOP2023000236A (es) 2024-02-29
CL2023003168A1 (es) 2024-04-12
BR112023022298A2 (pt) 2023-12-26
US20240246946A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
PH12021551317A1 (en) Modulators of trex1
ZA202310378B (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2023014307A (es) Inhibidores de proteasa como antivirales.
JOP20220142A1 (ar) مثبطات kras g12c
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
PH12021552805A1 (en) Cdk inhibitors
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
ZA202402178B (en) 3clpro protease inhibitor
PH12022551858A1 (en) Novel heterocyclic compounds useful as aurora a selective inhibitors
WO2021079196A3 (en) Mettl3 modulators
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020154499A8 (en) Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
PH12022551241A1 (en) Egfr inhibitors
PH12023553004A1 (en) Modulators of trex1
WO2019161157A8 (en) P300/cbp hat inhibitors
CR20230542A (es) Moduladores de trex1
MX2022005766A (es) Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
MX2009012704A (es) Inhibidores de transcriptasa inversa de no nucleosidos.
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.